Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 4 , Pages 665-679 , December 2006

Pathophysiology of insulin resistance

  • Giorgio Sesti, MD (Professor of Internal Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +39 0961 3697204; Fax: +39 0961 3697192.

References 

  1. DeFronzo RA. The triumvirate: β-cell, muscle or liver. A collusion responsible for NIDDM. Diabetes. 1988;37:667–687
  2. Shulman GI. Cellular mechanisms of insulin resistance. The Journal of Clinical Investigation. 2000;106:171–176
  3. DeFronzo RA, Tobin JD, Anders R. Glucose clamp technique: a model for quantifying insulin secretion and resistance. The American Journal of Physiology. 1979;237:E214–E223
  4. Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. The New England Journal of Medicine. 1990;322:223–228
  5. Bogardus C, Lillioja S, Stone K, et al. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. The Journal of Clinical Investigation. 1984;73:1185–1190
  6. Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Progress in Hormone Research. 2001;56:219–237
  7. Damsbo P, Vaag A, Hother-Nielsen O, et al. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 1991;34:239–245
  8. Kelley DE, Mintun MA, Watkins SC, et al. The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. The Journal of Clinical Investigation. 1996;97:2705–2713
  9. Rothman DL, Shulman RG, Shulman GI. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation. 1992;89:1069–1075
  10. Zierath JR, He L, Guma A, et al. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia. 1996;39:1180–1189
  11. Dohm GL, Tapscott EB, Pories WJ, et al. An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. The Journal of Clinical Investigation. 1988;82:486–494
  12. Eriksson J, Koranyi L, Bourey R, et al. Insulin resistance in Type II (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT4) gene in human skeletal muscle. Diabetologia. 1992;35:143–147
  13. Rothman DL, Magnusson I, Cline G, et al. Decreased muscle glucose transport/phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA. 1995;92:983–987
  14. Braithwaite SS, Palazuk B, Colca JR, et al. Reduced expression of hexokinase II in insulin-resistant diabetes. Diabetes. 1995;44:43–48
  15. Kruszynska YT, Mulford MI, Baloga J, et al. Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects. Diabetes. 1998;47:1107–1113
  16. Cline GW, Petersen KF, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. The New England Journal of Medicine. 1999;341:240–246
  17. Unger RH, Orci L. Lipotoxic diseases of nonadipose tissues in obesity. International Journal of Obesity and Related Metabolic Disorders. 2000;24(supplement 4):S28–S32
  18. Jacob S, Machann J, Rett K, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 1999;48:1113–1119
  19. Petersen KF, Hendler R, Price T, et al. 3C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes. 1998;47:381–386
  20. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789
  21. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. The Journal of Clinical Investigation. 1996;97:2859–2865
  22. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. The Journal of Clinical Investigation. 1999;103:253–259
  23. Gumà A, Zierath JR, Wallberg-Henriksson H, et al. Insulin induces translocation of GLUT-4 glucose transporters in human skeletal muscle. The American Journal of Physiology. 1995;268:E613–E622
  24. James DE, Strube MM, Mueckler MM. Molecular cloning and characterization of an insulin-regulatable glucose transporter. Nature. 1989;338:83–87
  25. Charron MJ, Brosius FC, Alper SL, et al. A glucose transport protein expressed predominately in insulin-sensitive tissues. Proceedings of the National Academy of Sciences of the USA. 1989;86:2535–2539
  26. Birnbaum MJ. Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell. 1989;57:305–315
  27. Shepherd PR, Khan BB. Glucose transporters and insulin action. The New England Journal of Medicine. 1999;341:248–2257
  28. Zierath JR, Krook A, Wallberg-Henriksson H. Insulin action and insulin resistance in human skeletal muscle. Diabetologia. 2000;43:821–835
  29. Sun XJ, Rothenberg P, Kahn CR, et al. Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature. 1991;352:73–77
  30. Sun XJ, Wang LM, Zhang Y, et al. Role of IRS-2 in insulin and cytokine signalling. Nature. 1995;377:173–177
  31. Sesti G, Federici M, Hribal ML, et al. Defects of the insulin receptor substrate (IRS) system in human metabolic disorders. FASEB J. 2001;15:2099–2111
  32. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799–806
  33. White MF. IRS proteins and the common path to diabetes. American Journal of Physiology. Endocrinology and Metabolism. 2001;283:E413–E422
  34. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. The Journal of Biological Chemistry. 1999;274:1865–1868
  35. Farese RV. Function and dysfunction of aPKC isoforms for glucose transport in insulin-sensitive and insulin-resistant states. American Journal of Physiology. Endocrinology and Metabolism. 2002;283:E1–E11
  36. Kane S, Sano H, Liu SCH, et al. A method to identify serine kinase substrates: Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. The Journal of Biological Chemistry. 2002;277:22115–22118
  37. Sano H, Kane S, Sano E, et al. Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. The Journal of Biological Chemistry. 2003;278:14599–14602
  38. Ullrich A, Bell RJ, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 1985;313:756–761
  39. Ebina Y, Ellis L, Jarnagin K, et al. The structural basis for hormone-activated transmembrane signalling. Cell. 1985;40:747–758
  40. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparision with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5:2503–2512
  41. Shier P, Watt VM. Primary structure of a putative receptor for a ligand of the insulin family. The Journal of Biological Chemistry. 1989;264:14605–14668
  42. Sesti G, Federici M, Lauro D, et al. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes/Metabolism Research and Reviews. 2001;17:363–373
  43. Mosthaf L, Grako D, Dull TJ, et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990;9:2409–2413
  44. Yamaguchi Y, Flier JS, Yokota A, et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology. 1991;129:2058–2066
  45. McClain DA. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Molecular Endocrinology. 1991;5:734–739
  46. Yamaguchi Y, Flier JS, Benecke H, et al. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology. 1993;132:1132–1138
  47. Leibiger B, Leibiger IB, Moede T, et al. Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. Molecular Cell. 2001;7:559–570
  48. Sesti G, Marini MA, Montemurro A, et al. Evidence that two naturally occurring human insulin receptor α-subunit variants are immunologically distinct. Diabetes. 1992;41:6–11
  49. Sesti G, Tullio AN, D'Alfonso R, et al. Tissue-specific expression of two alternatively spliced isoforms of the human insulin receptor protein. Acta Diabetologica. 1994;31:59–65
  50. Norgren S, Zierath J, Wedell A, et al. Regulation of human insulin receptor RNA splicing in vivo. Proceedings of the National Academy of Sciences of the USA. 1994;91:1465–1469
  51. Sesti G, D'Alfonso R, Vargas Punti MD, et al. Peptide-based radioimmunoassay for the two isoforms of the human insulin receptor. Diabetologia. 1995;38:445–453
  52. Sell SM, Reese D, Ossowski VM. Insulin-inducible changes in insulin receptor mRNA splice variants. The Journal of Biological Chemistry. 1994;269:30769–30772
  53. Mosthaf L, Vogt B, Haring HU, et al. Altered expression of insulin receptor types A and B in the skeletal muscle of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA. 1991;88:4728–4730
  54. Mosthaf L, Eriksson J, Haring HU, et al. Insulin receptor isotypes expression correlates with risk of non-insulin-dependent diabetes mellitus. Proceedings of the National Academy of Sciences of the USA. 1993;90:2633–2635
  55. Norgren S, Zierath J, Galuska D, et al. Differences in the ratio of RNA encoding two isoforms of the insulin receptor between control and NIDDM patients. Diabetes. 1993;42:675–681
  56. Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the human insulin receptor protein. The Journal of Clinical Investigation. 1992;89:2066–2070
  57. Anderson CM, Henry RR, Knudson PE, et al. Relative expression of insulin receptor isoforms does not differ in lean, obese, and noninsulin-dependent diabetes mellitus subjects. The Journal of Clinical Endocrinology and Metabolism. 1993;72:1380–1383
  58. Hansen T, Bjorbaek C, Vestergaard H, et al. Expression of insulin receptor spliced variants and their functional correlates in muscle from patients with non-insulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology and Metabolism. 1993;77:1500–1505
  59. Sesti G, Marini MA, Tullio AN, et al. Altered expression of the two naturally occurring human insulin receptor variants in isolated adipocytes of non-insulin-dependent diabetes mellitus patients. Biochemical and Biophysical Research Communications. 1991;181:1419–1424
  60. Kellerer M, Sesti G, Seffer E, et al. Altered pattern of insulin receptor isotypes in skeletal muscle membranes of Type II (non-insulin-dependent) diabetic subjects. Diabetologia. 1993;36:628–632
  61. Federici M, Porzio O, Zucaro L, et al. Distribution of insulin/insulin-like growth factor-I hybrid receptors in human tissues. Molecular and Cellular Endocrinology. 1997;129:121–126
  62. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. The Biochemical Journal. 1993;290:419–426
  63. Seely BL, Reichart DR, Takata Y, et al. A functional assessment of insulin/Insulin-like Growth Factor-I hybrid receptors. Endocrinology. 1995;136:1635–1641
  64. Federici M, Zucaro L, Porzio O, et al. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of non-insulin-dependent diabetes mellitus subjects. The Journal of Clinical Investigation. 1996;98:2887–2893
  65. Federici M, Porzio O, Zucaro L, et al. Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Molecular and Cellular Endocrinology. 1997;135:41–47
  66. Federici M, Porzio O, Lauro D, et al. Increased abundance of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of obese subjects is correlated with in vivo insulin sensitivity. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2911–2915
  67. Federici M, Lauro D, D'Adamo M, et al. Expression of insulin/IGF-I hybrid receptors is increased in skeletal muscle of patients with chronic primary hyperinsulinemia. Diabetes. 1998;47:87–92
  68. Spampinato D, Pandini G, Iuppa A, et al. Insulin/insulin-like growth factor-I hybrid receptors overexpression is not an early defect in insulin-resistant subjects. The Journal of Clinical Endocrinology and Metabolism. 2000;85:4219–4223
  69. Cusi K, DeFronzo R. Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. The Journal of Clinical Endocrinology and Metabolism. 2000;85:3077–3084
  70. Caro JF, Sinha MK, Raju SM, et al. Insulin receptor kinase in human skeletal muscle from obese subjects with and without Noninsulin Dependent Diabetes. The Journal of Clinical Investigation. 1987;79:1330–1337
  71. Goodyear LJ, Giorgino F, Sherman LA, et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. The Journal of Clinical Investigation. 1995;95:2195–2204
  72. Nolan JJ, Freidenberg G, Henery R, et al. Role of human skeletal muscle insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. The Journal of Clinical Endocrinology and Metabolism. 1994;78:471–477
  73. Arner P, Pollare T, Lithell H, et al. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and Type II (non-insulin-dependent) diabetes mellitus. Diabetologia. 1987;30:437–440
  74. Maegawa H, Shigeta Y, Egawa K, et al. Impaired autophosphorylation of insulin receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes. 1991;40:815–819
  75. Sinha MK, Pories WJ, Flickinger EG, et al. Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM. Diabetes. 1987;36:620–625
  76. Caro JF, Ittoop O, Pories WJ, et al. Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. The Journal of Clinical Investigation. 1986;78:249–258
  77. Brozinick JT, Roberts BR, Dohm GL. Defective Signaling Through Akt-2 and -3 But Not Akt-1 in Insulin-Resistant Human Skeletal Muscle Potential Role in Insulin Resistance. Diabetes. 2003;52:935–941
  78. Kim YB, Nikoulina SE, Ciaraldi TP, et al. Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. The Journal of Clinical Investigation. 1999;104:733–741
  79. Björnholm M, Kawano Y, Lehtihet M, et al. Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity are decreased in skeletal muscle from NIDDM subjects following in vivo insulin stimulation. Diabetes. 1997;46:524–527
  80. Krook A, Bjornholm M, Galuska D, et al. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes. 2000;49:284–292
  81. Smith U, Axelsen M, Carvalho E, et al. Insulin signaling and action in fat cells: association with insulin resistance and type 2 diabetes. Annals of the New York Academy of Sciences. 1999;892:119–126
  82. Krook A, Roth RA, Jiang XJ, et al. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from non-insulin-dependent diabetic subjects. Diabetes. 1998;47:1281–1286
  83. Beeson M, Sajan MP, Dizon M, et al. Activation of protein kinase C-ζ by insulin and phosphatidylinositol-3, 4,5-(PO4)3 is defective in muscle in type 2 diabetes and impaired glucose tolerance. Amelioration by rosiglitazone and exercise. Diabetes. 2003;52:1926–1934
  84. Kim Y-B, Kotani K, Ciaraldi TP, et al. Insulin-stimulated PKC- ζ /λ activity is reduced and PDK-1 activity is normal in muscle of insulin-resistant humans. Diabetes. 2003;52:1935–1942
  85. Sajan MP, Standaert ML, Bandyopadhyay G, et al. Impaired activation of protein kinase C-ζ by insulin and phosphatidylinositol-3,4,5-(PO4)3 is cultured preadipocyte-derived adipocytes and myotubes of obese subjects. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3994–3998
  86. Garvey WT, Maianu L, Zhu JH, et al. Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. The Journal of Clinical Investigation. 1998;101:2377–2386
  87. Dohm GL, Elton CW, Friedman JE, et al. Decreased expression of glucose transporters in muscle from insulin-resistant patients. The American Journal of Physiology. 1991;260:E459–E463
  88. Handberg A, Vaag A, Damsbo P, et al. Expression of insulin-regulatable glucose transporters in skeletal muscle from Type II (non-insulin-dependent) diabetic patients. Diabetologia. 1990;33:625–627
  89. Ahmad F, Considine RV, Goldstein BJ. Increased abundance of the receptor-type protein-tyrosine phosphatase LAR accounts for the elevated insulin receptor dephosphorylating activity in adipose tissue of obese human subjects. The Journal of Clinical Investigation. 1995;95:2806–2812
  90. Ahmad F, Azevedo JL, Cortright R, et al. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. The Journal of Clinical Investigation. 1997;100:449–458
  91. Ahmad F, Considine RV, Bauer TL, et al. Improved sensitivity to insulin in obese subjects following weight loss is accompanied by reduced protein-tyrosine phosphatases in adipose tissue. Metabolism. 1997;46:1140–1145
  92. Goldfine ID, Maddux BA, Youngren JF, et al. Role of PC-1 in the etiology of insulin resistance. Annals of the New York Academy of Sciences. 1999;892:204–222
  93. Youngren JF, Maddux BA, Sasson S, et al. Skeletal muscle content of membrane glycoprotein PC-1 in obesity. Relationship to muscle glucose transport. Diabetes. 1996;45:1324–1328
  94. Frittitta L, Youngren JF, Sbraccia P, et al. Increased adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is associated with a reduction of both whole body insulin sensitivity and insulin receptor tyrosine-kinase activity. Diabetologia. 1997;40:282–289
  95. Pickup JC, Mattock MB, Chusney GD, et al. Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes. Diabetes Care. 2004;27:813–823
  96. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American Journal of Physiology. Endocrinology and Metabolism. 2001;280:E745–E751
  97. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271:665–668
  98. Carlson CJ, Koterski S, Sciotti RJ, et al. Enhanced basal activation of mitogen-activated protein kinases in adipocytes from type 2 diabetes: potential role of p38 in the downregulation of GLUT4 expression. Diabetes. 2003;52:634–641
  99. Bouzakri K, Roques M, Gual P, et al. Reduced activation of phosphatidylinositol-3 kinase and increased serine 636 phosphorylation of insulin receptor substrate-1 in primary culture of skeletal muscle cells from patients with type 2 diabetes. Diabetes. 2003;52:1319–1325

PII: S1521-690X(06)00078-9

doi: 10.1016/j.beem.2006.09.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 4 , Pages 665-679 , December 2006

Article Tools

* Image Usage & Resolution